Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells

British Journal of Cancer

Volumn 84, Issue 8, 2001, Pages 1115-1121

  Withoff, S ^a   Bijman, M N A ^a   Stel, A J ^a   Delahaye, L ^a   Calogero, A ^a   De Jonge, M W A ^b   Kroesen, B J ^a   De Leij, L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b IQ Products   (Netherlands)

Author keywords

Bi specific antibody; BIS20x3; CD20; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

BISPECIFIC ANTIBODY; CD20 ANTIGEN; FAS ANTIGEN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; RITUXIMAB;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CROSS LINKING; CYTOTOXICITY TEST; DNA DEGRADATION; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOPHARMACOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD3; APOPTOSIS; B-LYMPHOCYTES; CELL FUSION; CELL LINE; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYBRIDOMAS; JURKAT CELLS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0035917642     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1707     Document Type: Article

References (30)

1. Bubien JK, Zhou LJ, Bell PD, Frizzell RA and Tedder TF (1993) Transfection of the CD20 cell surface molecule in ectopic cell types generates Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 121: 1121-1132
2. Chaperot L, Jacob MC, Molens JP, Manches O, Bensa JC and Plumas J (2000) From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas. Leuk Lymphoma 38: 247-263
3. Cochlovius B, Kipriyanov SM, Stassar MJJG, Christ O, Schuhmacher J, Strauß G, Moldenhauer G and Little M (2000) Treatment of human B cell lymphoma xenografts with a CD3×CD19 diabody and T cells. J Immunol 165: 888-895
4. Cragg MS, French RR and Glennie MJ (1999) Signalling antibodies in cancer therapy. Curr Opin Immunol 11: 541-547
5. Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dǒrken B and Pezzutto A (1998) Immunotherapy of B-cell lymphoma with CD3×19 bispecific antibodies: Co-stimulation via CD28 prevents "veto" apoptosis of antibody- targeted cytotoxic T cells. Blood 92: 4750-4757
6. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB and Johnson P(1995) Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. J Biol Chem 270: 22632-22638
7. Deans JP, Robbins SM, Polyak MJ and Savage JA (1998) Rapid distribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 273: 344-348
8. Helfrich W, Kroesen BJ, Roovers RC, Westers L, Molema G, Hoogenboom HR and De Leij L (1998) Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer 76: 232-239
9. Heijnen IAFM and Van De Winkel JGJ (1997) Human IgG Fc receptors. Int Rev Immunol 16: 29-56
10. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG and Mulkerrin MG (2000) Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164: 4178-4184
11. Kroesen BJ, Ter Haar A, Spakman H, Willemse P, Sleijfer DTh, De Vries EGE, Mulder NH, Berendsen HH, Limburg PC, the TH and De Leij L (1993) Local antitumour treatment in carcinoma patients with bi-specific-monoclonal- antibody-redirected T cells. Cancer Immunol Immunother 37: 400-407
12. Kroesen BJ, Bakker A, Van Lier RAW, The HT and De Leij L (1995) Bispecific antibody mediated target-cell specific costimulation of resting T-cells via CD5 and CD28. Cancer Res 55: 4409-4415
13. Kroesen BJ, Helfrich W, Molema G and De Leij L (1998) Bispecific antibodies for treatment of cancer in experimental animal models and man. Adv Drug Deliv Rev 31: 105-129
14. Lichtenfels R, Biddison WE, Schulz H, Vogt AB and Martin R (1994) CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Meth 172: 227-239
15. Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B and Bargou RC (2000) A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95: 2098-2103
16. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boue A and LeBlond V (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 11 (suppl 1): S113-S116
17. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 139: 271-279
18. Poppema S and Visser L (1987) Preparation and application of monoclonal antibodies: B cell panel and parafin tissue reactive panel. Biotest Bull 3: 131-139
19. Press OW, Farr AG, Borroz KI, Andersen SK and Martin PJ (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49: 4906-4912
20. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J and Pichlmayr R (1998) Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven- year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788-1794
21. Rosen ST (Guest Ed.) (1999) In: Recent advances and future directions using monoclonal antibodies for B-cell malignancies. Semin Oncol 26 (suppl 14): 2-122
22. Rudin CM and Thompson CD (1998) B-cell development and maturation. Semin Oncol 25:435-446
23. Shan D, Ledbetter JA and Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644-1652
24. Shan D, Ledbetter JA and Press OW (2000) Signaling events involved in anti-CD20- induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48: 673-683
25. Shresta S, Pham CTN, Thomas DA, Graubert TA and Ley TJ (1998) How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 10: 581-587
26. Tax WJM, Willems HW, Reekers PPM, Capel PJ and Koene RAP (1983) Polymorphism in mitogenic effect of 1gG1 monoclonal antibodies against T3 antigen on human T-cells. Nature 304: 445-447
27. Tedder TF and Engel P (1994) CD20: A regulator of cell cycle progression of B-lymphocytes. Immunol Today 15: 450-454
28. Van der Bruggen P, Bastin J, Gajewski T, Coulie P, Boel P, De Smet C, Traversers C, Townsend A and Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24: 3038-3043
29. Van Lier RA, Boot JH, De Groot ER and Aarden LA (1987a) Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur J Immunol 17: 1599-1604
30. Van Lier RA, Boot JH, Verhoeven AJ, De Groot ER, Brouwer M and Aarden LA (1987b) Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T-cells by epsilon-anti-CD3. J Immunol 139: 2873-2879